ENTYVIO®

(Vedolizumab)

Documentation

Patented
Approved 2014
FDA Letter
FDA Label
Full Sequence

Brief Summary

Function Type: Antagonist
Target: Integrin-α4β7
Indication Category: Autoimmunity

Approved Indications

Detailed Summary

Side Effects

References

Wikipedia
Drugs.com
FDA